COVID-19
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.
The U.K authorized AstraZeneca’s COVID-19 vaccine on Wednesday, but it could be April at the earliest before the drug will likely be administered in the United States, Operation Warp Speed’s chief said.
A great deal remains unknown about the SARS-CoV-2 virus, its mutations, transmissibility and long-term effects. Here’s what we do know.
Sinopharm, a Chinese biopharmaceutical company controlled by the state, announced that its COVID-19 vaccine candidate had an efficacy rate of 79% based on interim analysis of Phase III trials.
Keeping in mind that COVID-19 has dominated the news cycle, here are the top 10 stories of 2020 in no particular order.
Overnight, U.K. health authorities authorized the COVID-19 vaccine developed by AstraZeneca and Oxford University for emergency use.
Operation Warp Speed succeeded on the development component but is failing in the early stages of distribution. Here’s everything you need to know about it.
The U.S. Department of Defense awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine.
The United Kingdom is expected to give the green light to the vaccine developed by AstraZeneca and Oxford University this week.
PRESS RELEASES